Latest Pharma and Biotech News
Pharmaceutical
6 June 2025 In Latin America, the average percentage of the public budget for health is 12.75%, half of what is allocated by the 38 countries that make up the Organization for Economic Cooperation and Development (OECD), which on average is 24.5%.
Today's issue
Refine Search
Biotechnology
French pharma major Sanofi has started early global shipments of its monoclonal antibody Beyfortus (nirsevimab), aiming to shore up supply ahead of the 2025–2026 respiratory syncytial virus (RSV) season. Doses are being dispatched from early in the third quarter, giving healthcare providers more time to prepare for the season, which typically starts in November. Immunizations are expected to begin in the fall. 9 June 2025
Generics
The Russian pharmaceutical market, valued at around $41 billion, continues to be a magnet for Indian pharmaceutical companies. 9 June 2025
Biotechnology
US biotech PureTech Health is positioning its lead candidate LYT-100 as a potential disruptor in the treatment of idiopathic pulmonary fibrosis (IPF), a rare lung condition long underserved by current therapies. 9 June 2025
Pharmaceutical
The European Council of Minister last week said it is ready to begin negotiations with the European Parliament, having agreed its position on new rules that aim to make the European Union’s (EU) pharmaceutical sector fairer and more competitive. 9 June 2025
Pharmaceutical
Canada-based Knight Therapeutics and the US subsidiary of Japan’s Sumitomo Pharma have entered into exclusive license and supply agreements to commercialize certain products. 9 June 2025
Biotechnology
US biotech Regeneron Pharmaceuticals and French pharma major Sanofi on Saturday presented results from the DISCOVER Phase IV, single-arm, open-label trial assessing Dupixent (dupilumab) in adults and adolescents with moderate-to-severe atopic dermatitis with skin of color. 9 June 2025
Biotechnology
Regulatory news last week included US biotech Moderna receiving Food and Drug Administration (FDA) approval for its new COVID-19 Vaccine mNEXSPIKE. On the M&A front, French pharma major Sanofi announced it is punting more than $9 billion to acquire Blueprint Medicines and its Ayvakit, BLU-808 and immunology pipeline. USA-based Cullinan Therapeutics has entered into a license deal with China's Genrix Bio for the latter’s velinotamig for multiple myeloma. Also of note, RegeNXBio released what lookedlike good results for its investigational Duchenne muscular dystrophy drug RGX-202. 8 June 2025
Pharmaceutical
US drugmaker Vertex Pharmaceutical (Nasdaq: VRTX) has announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with cystic fibrosis transmembrane conductance regulator (CFTR) modulators and, in particular, its Alyftrek (vanzacaftor/tezacaftor/deutivacaftor). 7 June 2025
Pharmaceutical
In Latin America, the average percentage of the public budget for health is 12.75%, half of what is allocated by the 38 countries that make up the Organization for Economic Cooperation and Development (OECD), which on average is 24.5%. 6 June 2025
Pharmaceutical
US cardiorenal-focussed drugmaker Ardelyx announced that Mike Kelliher, formerly executive vice president, corporate development and strategy, has been promoted to chief business officer, and James Brady has joined the company as chief human resources officer. 6 June 2025
Biotechnology
Sweden’s Sobi and US biopharma Apellis Pharmaceuticals have presented new data from the open-label period of the Phase III VALIANT study, investigating Aspaveli/Empaveli (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). 6 June 2025
Biotechnology
Japan’s Otsuka today presented positive results from a pre-specified interim analysis of the Phase III VISIONARY study (NCT05248646) evaluating sibeprenlimab, for the treatment of immunoglobulin A nephropathy (IgAN) in adults. 6 June 2025
Biotechnology
China-based Kelun-Biotech Biopharmaceutical announced the placement of 5,918,000 H shares under its general mandate, representing approximately 2.54% of the enlarged share capital of the company post the placement. The shares were placed at HK$331.8 per share, raising net proceeds of around US$250 million. 6 June 2025
Biotechnology
The dynamics of the Friedreich's ataxia market are anticipated to change as companies across the globe work towards the development of new drug therapy options to treat this disease, according to a report from DelveInsight. 6 June 2025
Biotechnology
Texas-based ImmunoPrecise Antibodies, a leader in AI-driven biotherapeutics, closed 22% higher Thursday. 6 June 2025
Pharmaceutical
US biotech Trevi Therapeutics has raised around $115 million in a public stock offering, giving it fresh momentum to continue developing its investigational therapy Haduvio (nalbuphine) for chronic cough. 6 June 2025
Biotechnology
Genetic testing company 23andMe is preparing for a renewed auction of its assets after a federal judge agreed to reopen the sale process, following an eleventh hour bid from company co-founder Anne Wojcicki. 6 June 2025
Pharmaceutical
AstraZeneca has received European approval for a fixed-duration regimen of Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, for adults newly diagnosed with chronic lymphocytic leukemia (CLL). 6 June 2025
Pharmaceutical
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the use of German pharma major Bayer’s Nubeqa (darolutamide) for the treatment of adult patients with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT). 6 June 2025
Biotechnology
US commercial-stage drugmaker Corcept Therapeutics has presented results from its DAZALS study of dazucorilant in patients with amyotrophic lateral sclerosis (ALS) at the European Network to Cure ALS (ENCALS) 2025 annual meeting. 6 June 2025
All news
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk today announced headline results from REDEFINE 2, a Phase III trial in the global REDEFINE program. 10 March 2025
Biotechnology
Finnish drugmaker Orion Corporation has announced that it is establishing a new research and development (R&D) center in Cambridge, UK, during 2025 to accelerate its global growth strategy and the development of innovative medicines. 10 March 2025
Biotechnology
Shares of German biotech BioNTech dipped 2.5% to $105.86 today, after it reported financial results for the three months and full year ended December 31, 2024, and provided an update on its corporate progress. 10 March 2025
Pharmaceutical
Thought leaders from pharma are among the authors of a column tackling one of society’s toughest questions - what we should do to solve society’s obesity epidemic. 10 March 2025
Biotechnology
Indian drug major Sun Pharmaceutical Industries has entered an agreement with Checkpoint Therapeutics to acquire the US immunotherapy and targeted oncology company, with the news sending the latter’s shares rocketing more than 65% to $4.06 this morning. 10 March 2025
Biotechnology
The US Food and Drug Administration (FDA) has approved the biologics license application (BLA) for Encelto (revakinagene taroretcel-lwey; NT-501) for the treatment of macular telangiectasia type 2 (MacTel), submitted by privately-held US biotech Neurotech Pharmaceuticals. 10 March 2025
Biosimilars
US pharma major Bristol Myers Squibb has announced positive data from the pivotal Phase III POETYK PsA-2 trial evaluating the efficacy and safety of Sotyktu (deucravacitinib) in adults with active psoriatic arthritis (PsA). 10 March 2025
Pharmaceutical
Belgian biotech Agomab Therapeutics has reported positive interim results from its Phase IIa STENOVA trial of AGMB-129, an oral gut-restricted small molecule ALK5 inhibitor in development for fibrostenosing Crohn’s disease. The analysis includes data from 44 patients who completed 12 weeks of treatment, with the study meeting both its primary and secondary endpoints. 10 March 2025
Pharmaceutical
US pharma giant Pfizer today announced that James List, has joined the company as chief internal medicine officer. 10 March 2025
Pharmaceutical
Novartis has reported new data showing that its investigational BTK inhibitor, remibrutinib, significantly improves sleep quality for patients with chronic spontaneous urticaria (CSU). The findings, from the Phase III REMIX-1 and REMIX-2 trials, were presented at the American Academy of Dermatology annual meeting in Orlando. 10 March 2025
Biotechnology
Positive results from the ADEPT Phase II/III study indicate that Dupixent (dupilumab) may be effective in treating moderate-to-severe bullous pemphigoid (BP). The findings were presented at the 2025 American Academy of Dermatology Annual Meeting. 10 March 2025
Biotechnology
US biotech Amgen and Japanese partner Kyowa Kirin announced new results from the ongoing ROCKET Phase III clinical trial program evaluating rocatinlimab, an investigational T-cell rebalancing therapy targeting the OX40 receptor, in moderate to severe atopic dermatitis (AD). 10 March 2025
Pharmaceutical
Valo Therapeutics says it has successfully secured a financing round of 19 million euros ($20.6 million), part of which was raised in Europe and part in Australia, to clinically develop its innovative immune therapy for cancer. 10 March 2025
Pharmaceutical
The Bulgarian Association of Research-Based Pharmaceutical Manufacturers, ARPharM, says it is following the discussion of the National Health Insurance Fund (NHIF) budget for 2025 with attention and concern. 10 March 2025
Pharmaceutical
Last week’s significant research news included positive new Phase III data on Tezspire in nasal polyps from Amgen and AstraZeneca. US pharma major AbbVie became the latest entrant to the weight management sector, striking a deal with Gubra for its obesity candidate GUB14295. On the M&A front, Ireland-headquartered Jazz Pharmaceuticals announced it is acquiring Chimerix for around $935 million to expand its oncology portfolio. USA-based scPharmaceuticals gained US Food and Administration (FDA) approval for its supplemental new drug application (sNDA) for Furoscix in chronic kidney disease (CKD). 9 March 2025
Biosimilars
On Friday, the US Food and Drug Administration (FDA) approved as the first interchangeable biosimilar to Swiss pharma giant Roche's
anti-IgE monoclonal antibody Xolair (omalizumab). 8 March 2025
Pharmaceutical
Following swiftly after US regulatory clearance for the same indication for Odactra tablet brand, Danish allergy expert ALK Abello its Acarizax announced that Health Canada has approved tablet for use in children, aged five to 11, with house dust mite (HDM) allergy. 8 March 2025
Biotechnology
Nona Biosciences has introduced Hu-mAtrIx, an AI-assisted drug discovery platform designed to accelerate the identification and development of antibody-based therapies. 7 March 2025
Pharmaceutical
Marty Makary, nominated by Donald Trump to lead the Food and Drug Administration (FDA), has faced rigorous Senate scrutiny over recent agency job cuts and the abrupt cancellation of a flu vaccine advisory meeting. 7 March 2025
Generics
German generics and consumer healthcare major STADA Arzneimittel today released financial results, which the firm said continued its profitable growth journey in 2024 – supported by its strong commercial network in Europe, and complemented by a growing presence in the MENA, Eurasia and Asia-Pacific regions. 7 March 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze